Nathan Hale Fowler, MD, and Julie M. Vose, MD, MBA, on Follicular Lymphoma: Results From the RELEVANCE Trial

2018 ASCO Annual Meeting

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and Nathan Hale Fowler, MD, of The University of Texas MD Anderson Cancer Center, discuss phase III study findings on lenalidomide plus rituximab vs chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma (Abstract 7500).

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.